Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DI-Leu16-IL2 Extension in B-cell NHL
NCT02151903Phase 2Terminated
- Sponsor
- Alopexx Oncology, LLC
- Start
- Nov 2014
- Primary completion
- Jul 2016
- Modality
- Cytokines & Interferons, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of DI-Leu16-IL2 in B-cell non-Hodgkin lymphoma, sponsored by Alopexx Oncology, LLC. Started Nov 2014; status: terminated.
02
Drugs
DI-Leu16-IL2
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02151903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02151903.